The Middle East advanced cancer diagnostics market size was estimated at USD 1.32 billion in 2024 and is projected to reach USD 2.51 billion by 2030, growing at a CAGR of 7.30% from 2025 to 2033. The market for advanced cancer diagnostics in the Middle East is driven by several strong factors such as increasing prevalence of cancer, growing demand for early detection, launch of advanced diagnostic technologies, and investment under national healthcare modernization.
Breakthroughs such as liquid biopsy, AI-enabled pathology, and biomarker-driven companion diagnostics accelerate precision oncology, enabling more personalized and effective treatment. For instance, in June 2025, M42, AstraZeneca & SOPHiA GENETICS launched UAE liquid biopsy initiative to transform cancer care. As part of the collaboration, M42 will incorporate SOPHiA GENETICS' MSK-ACCESS, which is powered by SOPHiA DDM technology, into its testing infrastructure, allowing for non-invasive genomic profiling of cancers using a simple blood draw. This approach complements, not replaces, routine screenings and is designed for patients who are unable to undergo a solid tumor biopsy, allowing them to be matched with a precision therapy tailored to their specific cancer profile.
Further, governments across the country, particularly in the UAE, Qatar, and Saudi Arabia prioritize oncology care, implement national cancer control programs, and promote advanced diagnostic technologies like liquid biopsies, next-generation sequencing (NGS), and molecular imaging. Furthermore, the increasing number of specialized cancer centers and international collaborations hastened the adoption of precision diagnostics. Also, private sector participation and partnership with Middle East diagnostic firms improve access to cutting-edge tools and expertise.
Rapid technological advancements, evolving policy frameworks, and shifting healthcare priorities influence the market dynamics for advanced cancer diagnosis. Traditionally, cancer diagnosis and treatment were primarily determined by tumor location and stage, but the advent of advanced diagnostics has altered this paradigm. These new technologies provide detailed insights into cancer's molecular, genetic, and biological underpinnings, making precision medicine a reality. Advanced diagnostics reduce the likelihood of incorrect diagnoses while allowing for more personalized treatment selection. This precision reduces patient exposure to ineffective therapies and their associated side effects, while also allowing for real-time monitoring of treatment outcomes.
Public-private partnerships and collaborations, increasing adoption of precision medicine, and favorable reimbursement policies facilitating broader adoption of advanced diagnostic technologies are fueling market's growth. For instance, in March 2025, Lunit expanded its partnership with Saudi Arabia's largest medical group to deploy an AI Chest X-Ray Solution. This latest contract expands on Lunit's previous collaboration with HMG, which introduced Lunit INSIGHT MMG to support breast cancer screening across the Kingdom. The collaboration between Lunit and INSIGHT CXR aimed to improve diagnostic accuracy and efficiency in detecting critical chest abnormalities like lung cancer, pneumonia, and tuberculosis.
Favorable reimbursement policies and regulatory alignment, such as Saudi Arabia's Vision 2030 healthcare reforms and insurance expansions, contribute to the rapid adoption of advanced diagnostics. Furthermore, PPP-funded national awareness campaigns, technology transfer initiatives improve Country access, affordability of advanced diagnostic tools, and clinician training programs. The UAE's breast cancer diagnostics industry exemplifies this by leveraging public-private partnerships, AI-powered imaging, and liquid biopsy programs to improve early detection and precision treatment.
This product will be delivered within 2 business days.
Breakthroughs such as liquid biopsy, AI-enabled pathology, and biomarker-driven companion diagnostics accelerate precision oncology, enabling more personalized and effective treatment. For instance, in June 2025, M42, AstraZeneca & SOPHiA GENETICS launched UAE liquid biopsy initiative to transform cancer care. As part of the collaboration, M42 will incorporate SOPHiA GENETICS' MSK-ACCESS, which is powered by SOPHiA DDM technology, into its testing infrastructure, allowing for non-invasive genomic profiling of cancers using a simple blood draw. This approach complements, not replaces, routine screenings and is designed for patients who are unable to undergo a solid tumor biopsy, allowing them to be matched with a precision therapy tailored to their specific cancer profile.
Further, governments across the country, particularly in the UAE, Qatar, and Saudi Arabia prioritize oncology care, implement national cancer control programs, and promote advanced diagnostic technologies like liquid biopsies, next-generation sequencing (NGS), and molecular imaging. Furthermore, the increasing number of specialized cancer centers and international collaborations hastened the adoption of precision diagnostics. Also, private sector participation and partnership with Middle East diagnostic firms improve access to cutting-edge tools and expertise.
Rapid technological advancements, evolving policy frameworks, and shifting healthcare priorities influence the market dynamics for advanced cancer diagnosis. Traditionally, cancer diagnosis and treatment were primarily determined by tumor location and stage, but the advent of advanced diagnostics has altered this paradigm. These new technologies provide detailed insights into cancer's molecular, genetic, and biological underpinnings, making precision medicine a reality. Advanced diagnostics reduce the likelihood of incorrect diagnoses while allowing for more personalized treatment selection. This precision reduces patient exposure to ineffective therapies and their associated side effects, while also allowing for real-time monitoring of treatment outcomes.
Public-private partnerships and collaborations, increasing adoption of precision medicine, and favorable reimbursement policies facilitating broader adoption of advanced diagnostic technologies are fueling market's growth. For instance, in March 2025, Lunit expanded its partnership with Saudi Arabia's largest medical group to deploy an AI Chest X-Ray Solution. This latest contract expands on Lunit's previous collaboration with HMG, which introduced Lunit INSIGHT MMG to support breast cancer screening across the Kingdom. The collaboration between Lunit and INSIGHT CXR aimed to improve diagnostic accuracy and efficiency in detecting critical chest abnormalities like lung cancer, pneumonia, and tuberculosis.
Favorable reimbursement policies and regulatory alignment, such as Saudi Arabia's Vision 2030 healthcare reforms and insurance expansions, contribute to the rapid adoption of advanced diagnostics. Furthermore, PPP-funded national awareness campaigns, technology transfer initiatives improve Country access, affordability of advanced diagnostic tools, and clinician training programs. The UAE's breast cancer diagnostics industry exemplifies this by leveraging public-private partnerships, AI-powered imaging, and liquid biopsy programs to improve early detection and precision treatment.
Middle East Advanced Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, the analyst has segmented the Middle East advanced cancer diagnostics market report by test, end use, and country:Test Outlook (Revenue, USD Billion, 2021-2033)
- Tumor Marker Tests
- Fine Needle Aspiration Cytology (FNAC) & Biopsy
- Imaging-Based Diagnostics
- Bone Marrow Aspiration & Biopsy
- Immunohistochemistry (IHC) & Molecular Testing
- Genetic Testing for Cancer
- Liquid Biopsy
End Use Outlook (Revenue, USD Billion, 2021-2033)
- Hospitals & Cancer Specialty Centers
- Diagnostic Laboratories (Independent & Reference Labs)
- Research & Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Country Outlook (Revenue, USD Billion, 2021-2033)
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar
- Rest of Middle East
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Report Deliverables
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Technique Business Analysis
Chapter 5. End Use Business Analysis
Chapter 6. Country Business Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Middle East Advanced Cancer Diagnostics market report include:- Roche Diagnostics
- Illumina, Inc.
- Thermo Fisher Scientific
- Siemens Healthineers
- GE HealthCare
- Philips Healthcare
- Canon Medical Systems
- Fujifilm Holdings Corporation
- Agilent Technologies
- Bruker Corporation
- Becton, Dickinson and Company (BD)
- Bio-Rad Laboratories
- Myriad Genetics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | October 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 1.32 Billion |
| Forecasted Market Value ( USD | $ 2.51 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Middle East |
| No. of Companies Mentioned | 14 |
